Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.

BMC cancer - 23 Dec 2024

Alqahtani Tariq, Alsubait Arwa, Aloumi Meshari, Alamer Abdulrahman, Alomari Ghala, Alwassil Osama I, Obaidullah Ahmad J, Alghamdi Sahar S

Abstract excerpt

BACKGROUND: Medullary Thyroid Carcinoma (MTC) is closely associated with mutations in the RET proto-oncogene, placing the activated RET protein at the center of MTC pathogenesis. Existing therapeutic solutions, primarily tyrosine kinase inhibitors such as selpercatinib, vandetanib, and cabozantinib, have shown moderate efficacy but are accompanied by increased risks of side effects and resistance. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Neuroendocrine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to G-Quadruplexes

Share to High-Throughput Screening Assays

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39716145
DOI: 10.1186/s12885-024-13345-9
PMCID: PMC11665027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.PMID 39716145Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

Medullary Thyroid Cancer: Molecular Biology and Novel Molecular TherapiesSemantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.Semantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

Development of RET Kinase Inhibitors for Targeted Cancer TherapySemantic proximity Read ↗

RET kinase inhibitors: a review of recent patents (2012–2015)Semantic proximity Read ↗

Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.Semantic proximity Read ↗

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

The importance of the RET gene in thyroid cancer and therapeutic implications.Semantic proximity Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.